Pure Global: USA MedTech Security & Why FDA's Honeymoon Is Over

The FDA's "honeymoon phase" for medical device cybersecurity is over. In this episode, we dissect the agency's heightened scrutiny on premarket submissions, moving beyond simple documentation to active verification. We explore the new, unwritten rules manufacturers must follow to avoid costly rejections. We look at the case of a company whose 510(k) submission was delayed for months. Despite providing a complete Software Bill of Materials (SBOM), they were rejected because a common open-source library had a vulnerability. Their pain point was the failure to provide a VEX document to prove the vulnerability was not exploitable in their device, a detail that has become a silent requirement for approval. Key Takeaways: - Why is a complete SBOM no longer sufficient for an FDA submission? - How is the FDA using public databases to challenge your device's security in real-time? - What is a VEX document and how can it rescue your submission from an almost certain rejection? - Can you prove your Secure Product Development Framework is truly "built-in" and not just "bolted-on"? - What is the most critical question to answer about your vulnerability management plan? - How do you address the ticking time bomb of legacy device security? - What are the three essential components of a security narrative that the FDA now expects to see? For more information, contact us at [e-mail] or visit https://pureglobal.com/. Explore our FREE AI tools and medical device database at https://pureglobal.ai/.